CN113286798A - 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 - Google Patents

内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 Download PDF

Info

Publication number
CN113286798A
CN113286798A CN202080008964.4A CN202080008964A CN113286798A CN 113286798 A CN113286798 A CN 113286798A CN 202080008964 A CN202080008964 A CN 202080008964A CN 113286798 A CN113286798 A CN 113286798A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
compound
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080008964.4A
Other languages
English (en)
Other versions
CN113286798B (zh
Inventor
王喆
曾志宏
张磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Longwood Biopharmaceuticals Co Ltd
Original Assignee
Shanghai Longwood Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Longwood Biopharmaceuticals Co Ltd filed Critical Shanghai Longwood Biopharmaceuticals Co Ltd
Publication of CN113286798A publication Critical patent/CN113286798A/zh
Application granted granted Critical
Publication of CN113286798B publication Critical patent/CN113286798B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明涉及一种内环硫脒酰胺‑芳基酰胺类化合物及其治疗乙型肝炎的用途。具体地，本发明公开了一种可作HBV复制抑制剂，其具有化学式(A)所示结构的化合物或其立体异构体或互变异构体，或其药学上可接受的盐，水合物或溶剂化物，各基团的定义详见说明书。本发明还涉及包含上述化合物的药物组合物及其在治疗乙型肝炎中的用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080008964.4A 2019-01-11 2020-01-10 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 Active CN113286798B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019100275736 2019-01-11
CN201910027573.6A CN111434665B (zh) 2019-01-11 2019-01-11 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
PCT/CN2020/071523 WO2020143798A1 (zh) 2019-01-11 2020-01-10 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Publications (2)

Publication Number Publication Date
CN113286798A true CN113286798A (zh) 2021-08-20
CN113286798B CN113286798B (zh) 2022-08-02

Family

ID=71520539

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910027573.6A Active CN111434665B (zh) 2019-01-11 2019-01-11 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN202080008964.4A Active CN113286798B (zh) 2019-01-11 2020-01-10 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910027573.6A Active CN111434665B (zh) 2019-01-11 2019-01-11 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Country Status (12)

Country Link
US (1) US20220380384A1 (zh)
EP (1) EP3909957A4 (zh)
JP (1) JP2022517984A (zh)
KR (1) KR102650441B1 (zh)
CN (2) CN111434665B (zh)
AU (1) AU2020205923B2 (zh)
BR (1) BR112021013730A2 (zh)
CA (1) CA3126570A1 (zh)
MX (1) MX2021008386A (zh)
SG (1) SG11202107643YA (zh)
WO (1) WO2020143798A1 (zh)
ZA (1) ZA202105438B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
CN115177624A (zh) * 2021-04-06 2022-10-14 上海长森药业有限公司 通过口服给药增加病毒空衣壳蛋白治疗hbv的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108264520A (zh) * 2017-01-03 2018-07-10 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
WO2018153326A1 (zh) * 2017-02-22 2018-08-30 上海长森药业有限公司 磺酰肼类化合物及其用途
WO2019011323A1 (zh) * 2017-07-14 2019-01-17 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006394A1 (en) 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
CA2857344C (en) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Hepatitis b antiviral agents
CN110483484A (zh) * 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
CU24399B1 (es) * 2014-04-11 2019-04-04 Bayer Pharma AG Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108250121A (zh) * 2016-12-28 2018-07-06 上海长森药业有限公司 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途
CN108341810B (zh) * 2017-01-23 2022-01-18 上海长森药业有限公司 环硫脲类化合物及其用途
CN109251158B (zh) * 2017-07-14 2023-05-23 上海长森药业有限公司 硫脒酰胺类化合物及其用于乙型肝炎治疗的用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108264520A (zh) * 2017-01-03 2018-07-10 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
WO2018153326A1 (zh) * 2017-02-22 2018-08-30 上海长森药业有限公司 磺酰肼类化合物及其用途
WO2019011323A1 (zh) * 2017-07-14 2019-01-17 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN109843893A (zh) * 2017-07-14 2019-06-04 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
CN113286798B (zh) 2022-08-02
KR102650441B1 (ko) 2024-03-21
US20220380384A1 (en) 2022-12-01
KR20210134621A (ko) 2021-11-10
JP2022517984A (ja) 2022-03-11
BR112021013730A2 (pt) 2021-09-21
WO2020143798A1 (zh) 2020-07-16
AU2020205923B2 (en) 2022-12-01
CA3126570A1 (en) 2020-07-16
EP3909957A1 (en) 2021-11-17
ZA202105438B (en) 2022-09-28
CN111434665A (zh) 2020-07-21
SG11202107643YA (en) 2021-08-30
MX2021008386A (es) 2021-11-17
EP3909957A4 (en) 2022-09-07
CN111434665B (zh) 2023-03-10
AU2020205923A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
CN109843893B (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN108794487B (zh) 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
CN108250122B (zh) 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途
CN108264520B (zh) 用于治疗乙型肝炎的化合物及其用途
CN108341817B (zh) 硫脲类、脲类化合物及其用途
CN113286798B (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN108456216B (zh) 磺酰肼类化合物及其用途
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN110437232B (zh) 双并环脲类核衣壳抑制剂及其药物用途
CN108341810B (zh) 环硫脲类化合物及其用途
CN109251158B (zh) 硫脒酰胺类化合物及其用于乙型肝炎治疗的用途
CN110437132B (zh) 双并杂环核衣壳抑制剂及其药物用途
CN117865993A (zh) 一种aak1抑制剂及其制备和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40048134

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant